Anthony Capone has served Ambulnz’s executive team since 2017 and now serves DocGo as president, having previously served as DocGo CTO, and CPO. Mr. Capone holds a graduate CS degree in Artificial Intelligence from Clarkson University and has over 20 years of software engineering experience. His sterling record of entrepreneurial excellence includes leading three companies from start to successful exit. In addition to his roles at DocGo, Mr. Capone is a member of the Forbes Tech Council, writing on topics at the intersection of healthcare and AI.
Could you give us a brief overview and future vision for your company?
DocGo is a leading provider of last-mile mobile health services. DocGo is disrupting the traditional four-wall healthcare system by providing high quality, highly affordable care to patients where and when they need it. DocGo’s innovative technology and dedicated field staff of certified health professionals elevate the quality of patient care and drive business efficiencies for facilities, hospital networks, and health insurance providers. With Mobile Health, DocGo empowers the full promise and potential of telehealth by facilitating healthcare treatment, in tandem with a remote physician, in the comfort of a patient’s home or workplace. DocGo is able to deliver efficient, cost-effective mobile healthcare by leveraging proprietary logistics and scheduling technology, similar to those used in the ride-share industry – over time, we have invested over $40 million in our technology platform. Our goal is to further leverage our platform, our skilled clinicians, and nimble approach to broaden the breadth, depth and scope of healthcare services we provide.
DCGO recently reported Q2 results with great results from top line to bottom line. Congratulations! How many clinicians do you deploy and how many states does DCGO operate in?
DocGo has provided services in 29 US states and in the UK with over 4,000 full time employees, approximately 90% of those are in clinical roles. In addition, during periods of rapid growth the company can expand capacity through temporary staff. DocGo expects to hire an additional 600 full time employees in the second half of 2022.
DCGO is a growing company, and the labor market is challenging. What do you do to attract and retain new employees.
We offer a very attractive employment package that pays above the industry average in most of the markets where we operate, and we also invest in employee training. Full-time employees enjoy benefits including medical insurance and PTO, and are eligible to earn stock options which vest over a four-year period. This collective combination of attractive pay, increased training, industry-leading benefits and being a part of a team that is changing the way healthcare is delivered is very appealing and validated by our strong Glassdoor rating of 4.3.
You have a share repurchase program in place. Have any shares been repurchased to date?
Approximately 70,000 shares at an average cost of $7.10 have been repurchased to date. When we adopted the plan, the stock was in the mid $6 range. The buyback was put in place as part of a broader capital deployment strategy and to take advantage of the low valuation in our shares. We will continue to be opportunistic in our share repurchases.
Can you briefly describe the Hoverlance and tell us potential scenarios where it might be deployed?
The Hoverlance is a concept vehicle that establishes a bold vision for the future of emergency response – a vehicle that can rescue patients anywhere, via air, land or sea. It is currently being used for educational and promotional purposes. DocGo is constantly innovating – this line of thinking led us to also build and launch America’s first all electric ambulance, which has already been used to transport patients. This is the start of our Zero Emission initiative, which has the goal of converting our entire fleet to EV vehicles by 2032.
Covid testing has been a large part of the DCGO revenues. Do you expect to sustain that revenue through 2022?
Mass Covid testing revenues are expected to decline to insignificant amounts over the very near term, with the majority of programs having already been wound down. In most cases, we are transitioning directly into new non-Covid related programs with the same customer, so we expect relatively minimal disruption to revenues as a result.
Could DCGO grow to $1B in revenues?
We do not comment on our revenue outlook potential beyond our stated revenue guidance of $425-$435 million in 2022 and $40-$45 million in adjusted EBITDA. What we can say is that we have a very large untapped TAM in front of us with a proven model that customers are very excited about. We have an exceptional track record getting our foot in the door with high profile customers such as Carnival Cruise lines or the City of New York and then growing that customer relationship considerably. As a result, approximately 90% of DocGo revenues are generated from contracts in their third, fourth or fifth generation. In addition, DocGo’s mobile health NPS score, which is the industry standard for customer feedback, is an exceptional +77. The scoring scale is for that system is -100 to +100, with scores above 30 viewed as good and above 50 is great. We believe we have the vision, the team, the technology, a differentiated offering, and a growing customer base – now we just need to continue executing.
DCGO reports $200M in cash. Are you involved in any M&A talks or exploration? Would vertical or horizontal acquisitions make more sense to grow the company?
DocGo has stated publicly that we plan to be active on the M&A front with numerous proposed transactions in various stages of negotiation. We are looking at a range of companies that can potentially expand the breadth and depth of our service offerings or drive cost savings.
Analysts have a consensus target of $14.17 for DCGO shares representing an upside of nearly 40%. Does that seem like a viable near-term target for the company shares to you?
We see a significant growth opportunity ahead and our job is to continue building upon our track record of strong operational execution. As far as price targets go, we will leave that to our coverage analysts. What I can say is that we are extremely optimistic about DocGo’s role and growth potential in the ongoing transformation of how healthcare is delivered.
The Traders News Team
***The owners and operators of this website have NOT been compensated in any way for conducting or distributing this interview. Furthermore, we do not hold any form of equity in the publicly traded company/companies mentioned above***
Do we disclose any information to outside parties?
We do not sell your information to anyone.
What information do we collect?
We collect information from you when you subscribe to our newsletter or fill out a form on one of our social platforms. This includes your email address and or mobile phone number.
When registering on our site, as appropriate, you may be asked to enter your: e-mail address and or mobile number.
What do we use your information for?
When we collect your email or mobile number it is used for one purpose to send you the information you requested about small cap stocks. Please read our disclaimer carefully before viewing our emails.
Your information, whether public or private, will not be sold, exchanged, transferred, or given to any other company for any reason whatsoever, other than for the express purpose of delivering the information on small cap stocks that you requested.
We send periodic emails.
The email address you provide may be used to send you information, the small cap stock reports you requested, respond to inquiries, and/or other requests or questions.
How do we protect your information?
We implement a variety of security measures to maintain the safety of your personal information when you enter, submit, your email address. We use secure third parties to send email and sms messages to you.
Because we value your privacy we have taken the necessary precautions to be in compliance with the California Online Privacy Protection Act.
Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.
Please Note: TNS LLC and its employees are not a registered investment advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice.
All information on featured companies is provided by the companies profiled, or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D.
TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results.
In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement.
TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.
TNS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA. TNS LLC is not a Broker/Dealer and does not engage in high frequency trading.